SEC Form 4 · accession 0001562180-19-001029
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — President & CEO · Director
Period of report
Feb 13, 2019
Accepted (ET)
Feb 15, 2019 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $157.63 | Feb 13, 2019 | A | 50,000 | A | — | Feb 13, 2029 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The securities awarded on February 13, 2019 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 12,500 shares of common stock shall vest on the one year anniversary of February 13, 2019, with 37,500 shares vesting in 36 equal monthly installments thereafter.